AU732125B2 - Infectious papillomavirus pseudoviral particles - Google Patents

Infectious papillomavirus pseudoviral particles Download PDF

Info

Publication number
AU732125B2
AU732125B2 AU37256/97A AU3725697A AU732125B2 AU 732125 B2 AU732125 B2 AU 732125B2 AU 37256/97 A AU37256/97 A AU 37256/97A AU 3725697 A AU3725697 A AU 3725697A AU 732125 B2 AU732125 B2 AU 732125B2
Authority
AU
Australia
Prior art keywords
cells
papillomavirus
bpv
gene
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU37256/97A
Other languages
English (en)
Other versions
AU3725697A (en
Inventor
Douglas R Lowy
Richard B. Roden
John T Schiller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Government of the United States of America filed Critical US Department of Health and Human Services
Publication of AU3725697A publication Critical patent/AU3725697A/en
Application granted granted Critical
Publication of AU732125B2 publication Critical patent/AU732125B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU37256/97A 1996-07-17 1997-07-14 Infectious papillomavirus pseudoviral particles Expired AU732125B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2210496P 1996-07-17 1996-07-17
US60/022104 1996-07-17
PCT/US1997/012115 WO1998002548A2 (en) 1996-07-17 1997-07-14 Infectious papillomavirus pseudoviral particles

Publications (2)

Publication Number Publication Date
AU3725697A AU3725697A (en) 1998-02-09
AU732125B2 true AU732125B2 (en) 2001-04-12

Family

ID=21807834

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37256/97A Expired AU732125B2 (en) 1996-07-17 1997-07-14 Infectious papillomavirus pseudoviral particles

Country Status (8)

Country Link
US (2) US6599739B1 (https=)
EP (1) EP0922105B1 (https=)
JP (1) JP2000515741A (https=)
AT (1) ATE312178T1 (https=)
AU (1) AU732125B2 (https=)
CA (1) CA2257822A1 (https=)
DE (1) DE69734829D1 (https=)
WO (1) WO1998002548A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
AU6267000A (en) * 1999-06-30 2001-01-22 Evotec Oai Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
GB0007231D0 (en) 2000-03-24 2000-05-17 Chiron Spa Modified rna for gene delivery
US6841157B2 (en) * 2000-07-07 2005-01-11 Merck & Co., Inc. Production of chimeric human papillomavirus
FI116851B (fi) 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
CN1114690C (zh) * 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
AU2002367977B2 (en) 2001-08-13 2008-06-19 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
ITVA20050021A1 (it) 2005-04-01 2006-10-02 Sergio Biucchi Dispositivi informatici off-line per il sistema delle transazioni valutarie autogestite
WO2007064971A2 (en) * 2005-12-01 2007-06-07 The Government Of The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Infectious papovavirus particle comprising a cytocidal gene and methods of use thereof
WO2008082719A2 (en) * 2006-08-30 2008-07-10 University Of Rochester Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
WO2010118424A2 (en) * 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
EP3427755B1 (en) 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
WO2011017162A2 (en) * 2009-08-03 2011-02-10 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
CN107617110A (zh) * 2009-08-26 2018-01-23 西莱克塔生物科技公司 诱导t细胞辅助的组合物
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
MX385842B (es) 2013-09-18 2025-03-18 Aura Biosciences Inc Conjugados de partículas de tipo virus y uso de las mismas.
KR20180083868A (ko) 2015-10-30 2018-07-23 알레타 바이오쎄라퓨틱스, 인크. 종양 형질도입용 조성물 및 방법
WO2017075440A1 (en) 2015-10-30 2017-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Targeted cancer therapy
JP7115982B2 (ja) 2015-10-30 2022-08-09 アレタ・バイオセラピューティクス・インコーポレイテッド 癌の治療のための組成物及び方法
DE102016215500B4 (de) * 2016-08-18 2020-02-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Sensorsystem zur Charakterisierung des Zustandes von in einem Kultivierungsgefäß enthaltenen Proben einer heterogenen Biomassestruktur
IL269986B2 (en) 2017-04-12 2024-06-01 Aura Biosciences Inc Targeted combination therapy
EP3706783A1 (en) 2017-11-06 2020-09-16 The United States of America, as represented by the Secretary, Department of Health and Human Services Cancer treatment utilizing pre-existing microbial immunity
CN116350803B (zh) * 2023-05-19 2023-11-24 健通(济南)生物科技有限公司 一种以乳头瘤病毒样颗粒为载体的mRNA递药系统及制备方法
WO2026055208A1 (en) 2024-09-04 2026-03-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particle conjugates comprising photoactivatable dye compounds and methods of making and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5792931A (en) * 1994-08-12 1998-08-11 Pioneer Hi-Bred International, Inc. Fumonisin detoxification compositions and methods
WO1996011272A2 (de) 1994-10-07 1996-04-18 Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
FR2749323B1 (fr) 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
ES2572628T3 (es) * 1997-09-05 2016-06-01 Medimmune, Inc. Método in vitro para desmontaje/remontaje de partículas análogas al virus del papiloma humano (VLP)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEINO ET AL (1995) VIROL. 214, 349-359 *
RODEN ET AL (1996) J INVEST DERMATOL 106,912 *
ZHOU ET AL (1993) J GEN VIROL. 74, 763-768 *

Also Published As

Publication number Publication date
JP2000515741A (ja) 2000-11-28
EP0922105A2 (en) 1999-06-16
AU3725697A (en) 1998-02-09
DE69734829D1 (de) 2006-01-12
WO1998002548A2 (en) 1998-01-22
EP0922105B1 (en) 2005-12-07
ATE312178T1 (de) 2005-12-15
CA2257822A1 (en) 1998-01-22
US20030207446A1 (en) 2003-11-06
US6599739B1 (en) 2003-07-29
WO1998002548A3 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
AU732125B2 (en) Infectious papillomavirus pseudoviral particles
Day et al. The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains
EP1700911B1 (en) In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
Stauffer et al. Infectious human papillomavirus type 18 pseudovirions
Volpers et al. Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells
Okun et al. L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation
EP1292328B1 (en) Chimeric human papillomavirus (hpv) l1 molecules and uses therefor
Rossi et al. Assembly of human papillomavirus type 16 pseudovirions in Saccharomyces cerevisiae
US7351533B2 (en) In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
EP1305039B1 (en) Stable (fixed) forms of viral l1 capsid proteins, fusion proteins and uses thereof
US6380364B1 (en) Chimeric biotin-binding papillomavirus protein
AU753391B2 (en) Protein delivery system using human papillomavirus virus-like particles
Gašparić et al. Prophylactic DNA immunization against multiple papillomavirus types
KR100540043B1 (ko) 감염성 파필로마바이러스 위바이러스성 입자
EP1250593B1 (en) IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs)
US6962777B1 (en) In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
KR20050050115A (ko) 유두종바이러스의 2종 이상의 비구조적 초기 단백질을암호화하는 ｄｎａ 백신
US20030096259A1 (en) In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs), homogeneous VLP and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
Zheng et al. Stable high‐level expression of truncated human papillomavirus type 16 L1 protein in Drosophila Schneider‐2 cells
KR19990055876A (ko) 사람 파필로마바이러스 18형의 외피단백질 및 바이러스 유사입자의 제조

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)